Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04870905 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 |
| clinicaltrials |
| NCT04813705 | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 93 | Taizhou HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01882816 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05659186 | PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05652192 | SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC | recruiting | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05628922 | Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | terminated | Phase 2 | 4 | Emory UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05551767 | Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer | unknown | Phase 2 | 120 | City Clinical Oncology Hospital No 1OTHER_GOV | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT05484375 | Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 40 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01236547 | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05433597 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | not yet recruiting | Phase 2 / Phase 3 | 172 | Sun Yat-sen UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420597 | Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma | unknown | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417139 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00001277 | Studies of Elevated Parathyroid Activity | completed | Phase 2 | 1,553 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT04834206 | Nedaplatin in Treatment for Nasopharyngeal Carcinoma | completed | Phase 2 | 32 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05350891 | Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | unknown | Phase 2 | 77 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03854838 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04143984 | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 146 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05341193 | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04508816 | Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | completed | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04508829 | Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04921995 | Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma(RETICULA-NPC) | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05299437 | Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry(131THEROPT124) | unknown | Phase 2 | 50 | Carlo ChiesaOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03067610 | Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer(INFIELD) | completed | Phase 2 | 72 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04015336 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02562599 | Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | completed | Phase 2 | 60 | Hubei Cancer HospitalOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT02237924 | Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | completed | Phase 2 | 120 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02605967 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 122 | Novartis PharmaceuticalsINDUSTRY | 7 | Feb 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2023source: clinicaltrials